TABLE 6B - NEW PROCEDURE CODES
Procedure Code	Description	O.R.	MDC	MS-DRG
02HW3RZ*	Insertion of Short-term External Heart Assist System into Thoracic Aorta, Descending, Percutaneous Approach	Y	05	215
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
02LW0DJ^	Occlusion of Thoracic Aorta, Descending with Intraluminal Device, Temporary, Open Approach	Y	05	270, 271, 272
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""				981, 982, 983
02PW3RZ*	Removal of Short-term External Heart Assist System from Thoracic Aorta, Descending, Percutaneous Approach	Y	05	268, 269
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
02WW3RZ*	Revision of Short-term External Heart Assist System in Thoracic Aorta, Descending, Percutaneous Approach	Y	05	215
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
04L00DJ^	Occlusion of Abdominal Aorta with Intraluminal Device, Temporary, Open Approach	Y	05	268, 269
""			06	356, 357, 358
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0CSS0ZZ*	Reposition Larynx, Open Approach	Y	03	143, 144, 145
""			04	166, 167, 168
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0CSS7ZZ*	Reposition Larynx, Via Natural or Artificial Opening	Y	03	143, 144, 145
""			04	166, 167, 168
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0CSS8ZZ*	Reposition Larynx, Via Natural or Artificial Opening Endoscopic	Y	03	143, 144, 145
""			04	166, 167, 168
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0DH17JZ*	Insertion of Magnetic Lengthening Device into Upper Esophagus, Via Natural or Artificial Opening	N		
0DH27JZ*	Insertion of Magnetic Lengthening Device into Middle Esophagus, Via Natural or Artificial Opening	N		
0DH37JZ*	Insertion of Magnetic Lengthening Device into Lower Esophagus, Via Natural or Artificial Opening	N		
0P530Z3^	Destruction of Cervical Vertebra using Laser Interstitial Thermal Therapy, Open Approach	Y	03	143, 144, 145
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0P533Z3^	Destruction of Cervical Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Approach	Y	03	143, 144, 145
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0P534Z3^	Destruction of Cervical Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach	Y	03	143, 144, 145
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0P540Z3^	Destruction of Thoracic Vertebra using Laser Interstitial Thermal Therapy, Open Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0P543Z3^	Destruction of Thoracic Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0P544Z3^	Destruction of Thoracic Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0Q500Z3^	Destruction of Lumbar Vertebra using Laser Interstitial Thermal Therapy, Open Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0Q503Z3^	Destruction of Lumbar Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0Q504Z3^	Destruction of Lumbar Vertebra using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0Q510Z3^	Destruction of Sacrum using Laser Interstitial Thermal Therapy, Open Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0Q513Z3^	Destruction of Sacrum using Laser Interstitial Thermal Therapy, Percutaneous Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0Q514Z3^	Destruction of Sacrum using Laser Interstitial Thermal Therapy, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0WHC0GZ*	Insertion of Defibrillator Lead into Mediastinum, Open Approach	Y	04	166, 167, 168
""			05	265
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
0WHC3GZ*	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Approach	Y	04	166, 167, 168
""			05	265
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
0WHC4GZ*	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Endoscopic Approach	Y	05	265
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
0WPC0GZ*	Removal of Defibrillator Lead from Mediastinum, Open Approach	Y	01	040, 041, 042
""			05	265
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0WPC3GZ*	Removal of Defibrillator Lead from Mediastinum, Percutaneous Approach	Y	01	040, 041, 042
""			05	265
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0WPC4GZ*	Removal of Defibrillator Lead from Mediastinum, Percutaneous Endoscopic Approach	Y	01	040, 041, 042
""			05	265
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0WPCXGZ*	Removal of Defibrillator Lead from Mediastinum, External Approach	N		
0WWC0GZ*	Revision of Defibrillator Lead in Mediastinum, Open Approach	Y	01	040, 041, 042
""			05	265
""			09	579, 580, 581
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0WWC3GZ*	Revision of Defibrillator Lead in Mediastinum, Percutaneous Approach	Y	01	040, 041, 042
""			05	265
""			09	579, 580, 581
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0WWC4GZ*	Revision of Defibrillator Lead in Mediastinum, Percutaneous Endoscopic Approach	Y	01	040, 041, 042
""			05	265
""			09	579, 580, 581
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0WWCXGZ*	Revision of Defibrillator Lead in Mediastinum, External Approach	N		
302A3H0^	Transfusion of Autologous Whole Blood into Bone Marrow, Percutaneous Approach	N		
302A3H1^	Transfusion of Nonautologous Whole Blood into Bone Marrow, Percutaneous Approach	N		
302A3J0^	Transfusion of Autologous Serum Albumin into Bone Marrow, Percutaneous Approach	N		
302A3J1^	Transfusion of Nonautologous Serum Albumin into Bone Marrow, Percutaneous Approach	N		
302A3K0^	Transfusion of Autologous Frozen Plasma into Bone Marrow, Percutaneous Approach	N		
302A3K1^	Transfusion of Nonautologous Frozen Plasma into Bone Marrow, Percutaneous Approach	N		
302A3L0^	Transfusion of Autologous Fresh Plasma into Bone Marrow, Percutaneous Approach	N		
302A3L1^	Transfusion of Nonautologous Fresh Plasma into Bone Marrow, Percutaneous Approach	N		
302A3N0^	Transfusion of Autologous Red Blood Cells into Bone Marrow, Percutaneous Approach	N		
302A3N1^	Transfusion of Nonautologous Red Blood Cells into Bone Marrow, Percutaneous Approach	N		
302A3P0^	Transfusion of Autologous Frozen Red Cells into Bone Marrow, Percutaneous Approach	N		
302A3P1^	Transfusion of Nonautologous Frozen Red Cells into Bone Marrow, Percutaneous Approach	N		
302A3R0^	Transfusion of Autologous Platelets into Bone Marrow, Percutaneous Approach	N		
302A3R1^	Transfusion of Nonautologous Platelets into Bone Marrow, Percutaneous Approach	N		
5A09B5K	Assistance with Respiratory Ventilation, Less than 8 Consecutive Hours, Intubated Prone Positioning	N		
5A09C5K	Assistance with Respiratory Ventilation, 8-24 Consecutive Hours, Intubated Prone Positioning	N		
5A09D5K	Assistance with Respiratory Ventilation, Greater than 24 Consecutive Hours, Intubated Prone Positioning	N		
8E0U0EN*	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Open Approach	N		
8E0U3EN*	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Approach	N		
8E0U4EN*	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Endoscopic Approach	N		
8E0U7EN*	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening	N		
8E0U8EN*	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening Endoscopic	N		
8E0W0EN*	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Open Approach	N		
8E0W3EN*	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Approach	N		
8E0W4EN*	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Endoscopic Approach	N		
8E0W7EN*	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening	N		
8E0W8EN*	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening Endoscopic	N		
X051329*	Destruction of Renal Sympathetic Nerve(s) using Ultrasound Ablation, Percutaneous Approach, New Technology Group 9	Y	01	040, 041, 042
""			05	264
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2H03R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Inferior Vena Cava, Percutaneous Approach, New Technology Group 9	N		
X2H13R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Superior Vena Cava, Percutaneous Approach, New Technology Group 9	Y	01	040, 041, 042
""			04	166, 167, 168
""			05	252, 253, 254
""			06	356, 357, 358
""			07	423, 424, 425
""			08	515, 516, 517
""			10	628, 629, 630
""			11	673, 674, 675
""			12	715, 716, 717, 718
""			13	749, 750
""			14	769, 817, 818, 819
""			16	802, 803, 804
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2H20R9*	Insertion of Intraluminal Device, Bioprosthetic Valve into Right Femoral Vein, Open Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2H30R9*	Insertion of Intraluminal Device, Bioprosthetic Valve into Left Femoral Vein, Open Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
X2H63V9*	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Atrium, Percutaneous Approach, New Technology Group 9	Y	05	228, 229
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2HK3V9*	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Ventricle, Percutaneous Approach, New Technology Group 9	Y	05	228, 229
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2HL0F9*	Insertion of Conduit to Short-term External Heart Assist System into Right Axillary Artery, Open Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2HM0F9*	Insertion of Conduit to Short-term External Heart Assist System into Left Axillary Artery, Open Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2HX0F9*	Insertion of Conduit to Short-term External Heart Assist System into Thoracic Aorta, Ascending, Open Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2KH3D9*	Bypass Right Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2KH3E9*	Bypass Right Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2KJ3D9*	Bypass Left Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2KJ3E9*	Bypass Left Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""				981, 982, 983
X2U4079*	Supplement Coronary Artery/Arteries with Vein Graft Extraluminal Support Device(s), Open Approach, New Technology Group 9	Y	05	270, 271, 272
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""				981, 982, 983
X2UQ0P9	Supplement Right Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""				981, 982, 983
X2UR0P9	Supplement Left Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	Y	05	252, 253, 254
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""				981, 982, 983
XNHG0F9*	Insertion of Tibial Extension with Motion Sensors into Right Tibia, Open Approach, New Technology Group 9	N**	09	579, 580, 581
XNHH0F9*	Insertion of Tibial Extension with Motion Sensors into Left Tibia, Open Approach, New Technology Group 9	N**	09	579, 580, 581
XNR80D9	Replacement of Skull with Ultrasound Penetrable Synthetic Substitute, Open Approach, New Technology Group 9	Y	01	023, 024, 025, 026, 027
""			03	143, 144, 145
""			08	515, 516, 517
""			09	579, 580, 581
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	955
""				981, 982, 983
XNRL099*	Replacement of Right Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	Y	08	503, 504, 505
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XNRM099*	Replacement of Left Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	Y	08	503, 504, 505
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGJ0B9*	Fusion of Right Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	Y	08	492, 493, 494
""			10	628, 629, 630
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGK0B9*	Fusion of Left Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	Y	08	492, 493, 494
""			10	628, 629, 630
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGL0B9*	Fusion of Right Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	Y	08	503, 504, 505
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XRGM0B9*	Fusion of Left Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	Y	08	503, 504, 505
""			14	769, 817, 818, 819
""			17	823, 824, 825, 829, 830
""			18	853, 854, 855, 856, 857, 858
""			19	876
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
XW013G6^	Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N		
XW013L9*	Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	N		
XW013S9*	Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	N		
XW033K9*	Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9	N		
XW033P9*	Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9	N		
XW033Q9*	Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	N		
XW033R9*	Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9	N		
XW043K9*	Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9	N		
XW043P9*	Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9	N		
XW043Q9*	Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9	N		
XW043R9*	Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9	N		
XW053T9*	Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9	N		
XW0DXJ9*	Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9	N		
XW0DXK8^	Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8	N		
XW0DXN9*	Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9	N		
XW0G7K8^	Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8	N		
XW0H7K8^	Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8	N		
XW133H9	Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	N**	PRE	016, 017
XW133J8^	Transfusion of Exagamglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8	N**	PRE	016, 017
XW143H9	Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9	N**	PRE	016, 017
XW143J8^	Transfusion of Exagamglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8	N**	PRE	016, 017
XX20X89*	Monitoring of Brain Electrical Activity, Computer-aided Detection and Notification, New Technology Group 9	N		
XX2F3W9*	Monitoring of Musculoskeletal Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach, New Technology Group 9	N		
XXE2X19*	Measurement of Cardiac Output, Computer-aided Assessment, New Technology Group 9	N		
XXE5XY9*	Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9	N		

	Notes:
	(*)-These codes were discussed at the March 7, 2023 - March 8, 2023 ICD-10 Coordination and Maintenance Committee meeting and were not finalized in time to include in the proposed rule. They will be implemented on October 1, 2023.
	(^)-These codes were implemented on April 1, 2023.
	(**)-Non-OR procedure affects DRGs
